Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma - ScienceDirect
g113791bci003.gif
Myocet (Teva) | Bioz | Ratings For Life-Science Research
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial - Gynecologic Oncology
Clinical available passive targeting nanomedicines | Download Table
Is Teva late reporting EU clinical trials?
Myocet (Teva) | Bioz | Ratings For Life-Science Research
Liposomal Doxorubicin Market Size, Share | Industry Report, 2013-2024
Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study
Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification - The Breast
Myocet (Teva) | Bioz | Ratings For Life-Science Research
LEKsykon - informacje o leku Myocet®
Liposomal Doxorubicin Market Global Industry Analysis, Segments, Top Key Players, Drivers and Forecasts To 2024
MYOCET - Cephalon (UK) Limited Trademark Registration
Myocet : Uses, Side Effects, Interactions, Dosage / Pillintrip
Myocet (Teva) | Bioz | Ratings For Life-Science Research
Doxorubicin | C27H29NO11 - PubChem
Myocet (Teva) | Bioz | Ratings For Life-Science Research
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come | Pharmacological Reviews
Teva Is a Hold
Nanomaterials | Free Full-Text | From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions | HTML
Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
